Which CGM system do you prefer? 1) Dexcom C5 2) Abbott Freestyle Libre 3) Medtronic Elite 4) Either 5) None Follow the link to see how you and your colleagues compare.

A 51-year-old patient returns to your office for a follow-up visit. She is currently taking metformin and glipizide after being diagnosed with type 2 diabetes 8 years ago. She shows you her self-care logs that indicate she has been eating a healthy diet and walking daily. She has been maintaining her weight (BMI 26kg/m2). Despite her excellent efforts, her A1C is 7.8%, above her target of A1C<7.0%. When you start to discuss adding a basal insulin dose to her regimen, she bursts into tears. All of the following are common barriers to insulin therapy initiations EXCEPT: A. Fear that hyperglycemia will make her ill. B. Fear others will treat her differently because she needs regular injections. C. Fear of needles or that insulin injections are painful. D. Fear that insulin causes death or complications. Follow the link to see the answer.

Mark Peyrot is Professor of Sociology at Loyola University Maryland and Professor of Health and Social Sciences at Bergen University College (Norway). He formerly was a faculty member in the departments of Sociology and Medicine at the University of Kentucky and Medicine at Johns Hopkins University.

In this Exclusive Interview, Mark Peyrot talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, CA about the importance of addressing the psychosocial needs of diabetes patients.

In this Exclusive Interview, Mark Peyrot talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, CA about the importance of addressing the psychosocial needs of diabetes patients.

I remember when I got the call to be on an advisory board for the first SGLT-2 inhibitor. The science made sense but it seemed that everyone was worried about the “tremendous” risk of UTI’s due to excess urination and glucose in the urine. I think this came from a …

In part 1 of this Exclusive Interview, Mark Peyrot talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, CA about his work in the field of behavioral diabetes research.

In part 2 of this Exclusive Interview, Mark Peyrot explains the ADA psycho-social guidelines in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, CA.

In part 3 of this Exclusive Interview, Mark Peyrot talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, CA about the key facets to the guidelines and how healthcare providers can use them to help in the care of their patients.

In part 4 of this Exclusive Interview, Mark Peyrot talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, CA about ways healthcare providers can effectively implement these guidelines into their busy appointments with their patients.